시장보고서
상품코드
1274400

세계의 전신홍반루푸스 치료 시장 보고서(2023년)

Systemic Lupus Erythematosus Treatment Global Market Report 2023

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 250 Pages | 배송안내 : 2-10일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

전신홍반루푸스 치료(Systemic Lupus Erythematosus Treatment) 시장은 2023년 25억 달러에서 27억 4,000만 달러로 CAGR 9.54%을 기록하며 성장할 것으로 예측됩니다. 러시아-우크라이나 전쟁은 적어도 단기적으로 COVID-19 팬데믹의 세계 경제 회복의 가능성을 혼란시켰습니다. 이 두 국가 간의 전쟁은 여러 국가에 대한 경제 제재, 상품 가격 상승, 공급망 혼란으로 이어졌으며, 상품과 서비스 전반에 인플레이션을 일으켜 전세계 많은 시장에 영향을 미쳤습니다. 전신홍반루푸스 치료 시장은 CAGR 9.84%로 추이하여 2027년 39억 8,000만 달러에 이를 것으로 예상됩니다.

2022년 전신홍반루푸스 치료 시장에서 북미가 가장 큰 지역이었습니다. 이 보고서의 대상 지역은 아시아 태평양, 서유럽, 동유럽, 북미, 남미, 중동 및 아프리카입니다.

자가면역 질환 증가는 향후 전신홍반루푸스 치료 시장 성장을 촉진할 것으로 예상됩니다. 자가면역 질환은 환자의 면역계가 자신의 몸을 공격하는 상태를 말합니다. 자가면역 질환은 면역체계가 신체의 일부를 이물질로 오인함으로써 발생합니다. 신체는자가 항체라고 불리는 단백질을 방출하고 건강한 세포를 공격합니다. 전신홍반루푸스는 면역계가 조직을 공격하고 감염된 기관에 광범위한 염증과 조직 손상을 일으키는 자가 면역 질환을 의미합니다. 관절, 피부, 뇌, 폐, 신장, 혈관 등에 영향을 미칩니다. 예를 들어 2020년 6월 자가면역 관련 미국의 비영리 단체인 미국 자가면역관련질병협회(AARDA)가 공유한 보고서에 따르면 5,000만명의 미국인이 자가면역질환을 앓고 있으며, 연간 860억 달러의 비용이 소요될 것으로 추정됩니다. 또한 2021년 10월 영국의 공공 연구 대학인 런던 시티 대학교가 공유한 기사에 따르면 영국에서는 인구의 7%에 해당하는 400만명이 적어도 하나의 자가면역질환을 가지고 있다고 추정되고 있습니다. 80개가 넘는 자가면역 질환이 발견되었으며, 그 유병률은 매년 3-9%씩 증가하고 있습니다. 따라서, 자가면역 질환 증가는 전신홍반루푸스 치료 시장 성장을 이끌고 있습니다.

목차

제1장 주요 요약

제2장 전신홍반루푸스 치료 시장 특징

제3장 전신홍반루푸스 치료 시장 동향 및 전략

제4장 전신홍반루푸스 치료 시장-거시 경제 시나리오

  • COVID-19가 전신홍반루푸스 치료 시장에 미치는 영향
  • 러시아-우크라이나 전쟁이 전신홍반루푸스 치료 시장에 미치는 영향
  • 높은 인플레이션이 전신홍반루푸스 치료 시장에 미치는 영향

제5장 전신홍반루푸스 치료 시장 규모 및 성장

  • 세계의 전신홍반루푸스 치료 시장 실적(2017-2022년)
    • 시장의 촉진 요인
    • 시장의 억제 요인
  • 세계의 전신홍반루푸스 치료 시장 예측(2022-2027년, 2032년)
    • 시장의 촉진 요인
    • 시장의 억제 요인

제6장 전신홍반루푸스 치료 시장 세분화

  • 세계의 전신홍반루푸스 치료 시장, 약물별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)
  • 항말라리아제
  • 비스테로이드성 항염증제(NSAIDS)
  • 코르티코스테로이드
  • 면역억제약
  • 기타 약물
  • 세계의 전신홍반루푸스 치료 시장, 투여 경로별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)
  • 피하
  • 경구
  • 정맥내
  • 세계의 전신홍반루푸스 치료 시장, 용도별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)
  • 병원 약국
  • 소매 약국
  • 온라인 판매

제7장 전신홍반루푸스 치료 시장-지역 및 국가별 분석

  • 세계의 전신홍반루푸스 치료 시장, 지역별, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)
  • 세계의 전신홍반루푸스 치료 시장, 국가별, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)

제8장 아시아 태평양의 전신홍반루푸스 치료 시장

  • 아시아 태평양의 전신홍반루푸스 치료 시장 개요
  • 지역 정보, COVID-19의 영향, 시장 정보, 배경 정보, 정부의 대처, 규제, 규제 기관, 주요 단체, 과세액, 법인세 구조, 투자, 주요 기업
  • 아시아 태평양의 전신홍반루푸스 치료 시장, 약물별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)
  • 아시아 태평양의 전신홍반루푸스 치료 시장, 용도별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)

제9장 중국의 전신홍반루푸스 치료 시장

  • 중국의 전신홍반루푸스 치료 시장 개요
  • 중국의 전신홍반루푸스 치료 시장, 약물별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)
  • 중국의 전신홍반루푸스 치료 시장, 용도별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)

제10장 인도의 전신홍반루푸스 치료 시장

  • 인도의 전신홍반루푸스 치료 시장, 약물별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)
  • 인도의 전신홍반루푸스 치료 시장, 용도별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)

제11장 일본의 전신홍반루푸스 치료 시장

  • 일본의 전신홍반루푸스 치료 시장, 약물별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)
  • 일본의 전신홍반루푸스 치료 시장, 용도별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)

제12장 호주의 전신홍반루푸스 치료 시장

  • 호주의 전신홍반루푸스 치료 시장, 약물별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)
  • 호주의 전신홍반루푸스 치료 시장, 용도별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)

제13장 인도네시아의 전신홍반루푸스 치료 시장

  • 인도네시아의 전신홍반루푸스 치료 시장, 약물별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)
  • 인도네시아의 전신홍반루푸스 치료 시장, 용도별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)

제14장 한국의 전신홍반루푸스 치료 시장

  • 한국의 전신홍반루푸스 치료 시장, 약물별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)
  • 한국의 전신홍반루푸스 치료 시장, 용도별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)

제15장 서유럽의 전신홍반루푸스 치료 시장

  • 서유럽의 전신홍반루푸스 치료 시장 개요
  • 서유럽의 전신홍반루푸스 치료 시장, 약물별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)
  • 서유럽의 전신홍반루푸스 치료 시장, 용도별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)

제16장 영국의 전신홍반루푸스 치료 시장

  • 영국의 전신홍반루푸스 치료 시장, 약물별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)
  • 영국의 전신홍반루푸스 치료 시장, 용도별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)

제17장 독일의 전신홍반루푸스 치료 시장

  • 독일의 전신홍반루푸스 치료 시장, 약물별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)
  • 독일의 전신홍반루푸스 치료 시장, 용도별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)

제18장 프랑스의 전신홍반루푸스 치료 시장

  • 프랑스의 전신홍반루푸스 치료 시장, 약물별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)
  • 프랑스의 전신홍반루푸스 치료 시장, 용도별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)

제19장 동유럽의 전신홍반루푸스 치료 시장

  • 동유럽의 전신홍반루푸스 치료 시장 개요
  • 동유럽의 전신홍반루푸스 치료 시장, 약물별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)
  • 동유럽의 전신홍반루푸스 치료 시장, 용도별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)

제20장 러시아의 전신홍반루푸스 치료 시장

  • 러시아의 전신홍반루푸스 치료 시장, 약물별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)
  • 러시아의 전신홍반루푸스 치료 시장, 용도별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)

제21장 북미의 전신홍반루푸스 치료 시장

  • 북미의 전신홍반루푸스 치료 시장 개요
  • 북미의 전신홍반루푸스 치료 시장, 약물별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)
  • 북미의 전신홍반루푸스 치료 시장, 용도별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)

제22장 미국의 전신홍반루푸스 치료 시장

  • 미국의 전신홍반루푸스 치료 시장 개요
  • 미국의 전신홍반루푸스 치료 시장, 약물별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)
  • 미국의 전신홍반루푸스 치료 시장, 용도별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)

제23장 남미의 전신홍반루푸스 치료 시장

  • 남미의 전신홍반루푸스 치료 시장 개요
  • 남미의 전신홍반루푸스 치료 시장, 약물별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)
  • 남미의 전신홍반루푸스 치료 시장, 용도별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)

제24장 브라질의 전신홍반루푸스 치료 시장

  • 브라질의 전신홍반루푸스 치료 시장, 약물별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)
  • 브라질의 전신홍반루푸스 치료 시장, 용도별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)

제25장 중동의 전신홍반루푸스 치료 시장

  • 중동의 전신홍반루푸스 치료 시장 개요
  • 중동의 전신홍반루푸스 치료 시장, 약물별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)
  • 중동의 전신홍반루푸스 치료 시장, 용도별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)

제26장 아프리카의 전신홍반루푸스 치료 시장

  • 아프리카의 전신홍반루푸스 치료 시장 개요
  • 아프리카의 전신홍반루푸스 치료 시장, 약물별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)
  • 아프리카의 전신홍반루푸스 치료 시장, 용도별 세분화, 실적 및 예측(2017-2022년, 2022-2027년, 2032년)

제27장 전신홍반루푸스 치료 시장-경쟁 상황 및 기업 개요

  • 전신홍반루푸스 치료 시장-경쟁 상황
  • 전신홍반루푸스 치료 시장-기업 개요
    • GlaxoSmithKline PLC
    • Aurinia Pharmaceuticals
    • Pfizer
    • Merck &Co
    • Anthera Pharmaceuticals

제28장 전신홍반루푸스 치료 시장-주요 합병 및 인수

제29장 전신홍반루푸스 치료 시장-향후 전망 및 잠재력 분석

제30장 부록

LYJ 23.05.25

“Systemic Lupus Erythematosus Treatment Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on systemic lupus erythematosus treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for systemic lupus erythematosus treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The systemic lupus erythematosus treatment market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Drug: Antimalarial Drugs; Non-Steroidal Anti-Inflammatory Drugs (NSAIDS); Corticosteroids; Immunosuppressive Drugs
  • 2) By Route Of Administration: Sub-Cutaneous; Oral; Intravenous
  • 3) By Application: Hospital Pharmacies; Retail Pharmacies; Online Sales
  • Companies Mentioned: GlaxoSmithKline PLC; Aurinia Pharmaceuticals; Pfizer; Merck & Co; Anthera Pharmaceuticals
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the systemic lupus erythematosus treatment market are GlaxoSmithKline PLC, Aurinia Pharmaceuticals, Pfizer, Merck & Co, Anthera Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb Company, Inc., F. Hoffmann-La Roche Ltd., ImmuPharma PLC, Sanofi, Eli Lilly, Amgen, Inc., Johnson & Johnson Services, Inc., Lycera Corporation and Mylan NV.

The global systemic lupus erythematosus treatment market is expected to grow from $2.50 billion in 2023 to $2.74 billion in 2023 at a compound annual growth rate (CAGR) of 9.54%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The systemic lupus erythematosus treatment market is expected to reach $3.98 billion in 2027 at a CAGR of 9.84%.

The systemic lupus erythematosus treatment market consists of sales of systemic lupus erythematosus drugs including antimalarial drugs such as chlorquine, and hydrochlorquine, cytotoxic, and immunosuppressive drugs such as cyclosporine, cyclophosphamide, methotrexate, mycophenolate mofetil, tacrolimus, non-steroidal anti-inflammatory drugs such as ibuprofen, naproxen, biologics such as b-cell modulators, t-cell modulators, pro-inflammatory, as well as cytokine inhibitors, corticosteroids such as prednisone, hydrocortisone, dexamethasone, and other drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Systemic lupus erythematosus refers to an autoimmune disease that causes the immune system to attack its own tissues, causing widespread inflammation and tissue damage in the affected organs. It affects the joints, skin, brain, lungs, kidneys, and blood vessels. It is the most common type of lupus and cannot be cured, but medical interventions and lifestyle changes can help control it. Treatment for systemic lupus erythematosus consists mostly of immunosuppressive drugs that inhibit the immune system's activity.

North America was the largest region in the systemic lupus erythematosus treatment market in 2022. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The major types of drugs in systemic lupus erythematosus treatment are antimalarial drugs, non-steroidal anti-inflammatory drugs (NSAIDS), corticosteroids, and immunosuppressive drugs. An antimalarial is a drug that prevents or treats malaria. Lupus symptoms can be effectively treated with anti-malaria drugs such as hydroxychloroquine (Plaquenil), chloroquine (Aralen), and quinacrine (Atabrine). By route of administration, it is segmented into subcutaneous, oral, and intravenous. Systemic lupus erythematosus treatment is used in several applications, such as hospital pharmacies, retail pharmacies, and online sales.

The rising number of autoimmune disorders is expected to propel the growth of the systemic lupus erythematosus treatment market going forward. An autoimmune disease refers to a condition in which a patient's immune system attacks his or her body. An autoimmune disease occurs when the immune system mistakes parts of the body as foreign. The body releases proteins called autoantibodies that attack healthy cells. Systemic lupus erythematosus refers to an autoimmune disease that causes the immune system to attack its tissues, causing widespread inflammation and tissue damage in the affected organs. It affects the joints, skin, brain, lungs, kidneys, and blood vessels. For instance, in June 2020, according to a report shared by the American Autoimmune Related Diseases Association (AARDA), a US-based nonprofit organization dedicated to autoimmune awareness, it was estimated that as many as 50 million Americans lived with an autoimmune disease, which cost $86 billion a year. Furthermore, in October 2021, according to an article shared by the City, University of London, a UK-based public research university, 4 million people in the UK, or 7% of the population, are estimated to have at least one autoimmune disease. Over 80 autoimmune disorders have been found, and their prevalence is increasing annually by 3-9%. Thus, the rising number of autoimmune disorders is driving the growth of the systemic lupus erythematosus treatment market.

The introduction of improved biologic agents is a key trend gaining popularity in the systemic lupus erythematosus treatment market. A biologic agent refers to a substance that is made from a living organism or its products and is used for the prevention, diagnosis, or treatment of cancer and other diseases. Major companies operating in the market are advancing toward the development of biologic agents that would be used to treat systemic lupus erythematosus in various age groups. For instance, in December 2020, GlaxoSmithKline plc, a UK-based pharmaceutical and biotechnology company, announced the approval of BENLYSTA (belimumab) by the US Food and Drug Administration (FDA) for treating adult patients with active lupus nephritis (LN). Systemic lupus erythematosus (SLE) causes lupus nephritis, an inflammation of the kidneys. Benlysta is used for treating both SLE and LN. This approval also includes SLE and LN with both intravenous and subcutaneous formulations.

In March 2021, Merck, a US-based pharmaceutical company, acquired Pandion Therapeutics for $1.85 billion. Through this acquisition, Merck gained the TALON technology from Pandion Therapeutics, which would address unmet needs in autoimmune conditions by rebalancing the immune response. Pandion Therapeutics is a US-based biotechnology company focusing on developing novel therapeutics. The company's lead candidate, PT101, is an engineered IL-2 mutein combined with a protein backbone. PT101 treats autoimmune diseases, such as ulcerative colitis and systemic lupus erythematosus, by activating and expanding Tregs.

The countries covered in the systemic lupus erythematosus treatment market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The sytemic lupus erythematosus treatment market research report is one of a series of new reports from The Business Research Company that provides sytemic lupus erythematosus treatment market statistics, including sytemic lupus erythematosus treatment industry global market size, regional shares, competitors with a sytemic lupus erythematosus treatment market share, detailed sytemic lupus erythematosus treatment market segments, market trends and opportunities, and any further data you may need to thrive in the sytemic lupus erythematosus treatment industry. This sytemic lupus erythematosus treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Table of Contents

1. Executive Summary

2. Systemic Lupus Erythematosus Treatment Market Characteristics

3. Systemic Lupus Erythematosus Treatment Market Trends And Strategies

4. Systemic Lupus Erythematosus Treatment Market - Macro Economic Scenario

  • 4.1. COVID-19 Impact On Systemic Lupus Erythematosus Treatment Market
  • 4.2. Ukraine-Russia War Impact On Systemic Lupus Erythematosus Treatment Market
  • 4.3. Impact Of High Inflation On Systemic Lupus Erythematosus Treatment Market

5. Systemic Lupus Erythematosus Treatment Market Size And Growth

  • 5.1. Global Systemic Lupus Erythematosus Treatment Historic Market, 2017-2022, $ Billion
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints On The Market
  • 5.2. Global Systemic Lupus Erythematosus Treatment Forecast Market, 2022-2027F, 2032F, $ Billion
    • 5.2.1. Drivers Of The Market
    • 5.2.2. Restraints On the Market

6. Systemic Lupus Erythematosus Treatment Market Segmentation

  • 6.1. Global Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Antimalarial Drugs
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
  • Corticosteroids
  • Immunosuppressive Drugs
  • Other Drugs
  • 6.2. Global Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Sub-Cutaneous
  • Oral
  • Intravenous
  • 6.3. Global Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Sales

7. Systemic Lupus Erythematosus Treatment Market Regional And Country Analysis

  • 7.1. Global Systemic Lupus Erythematosus Treatment Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 7.2. Global Systemic Lupus Erythematosus Treatment Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

8. Asia-Pacific Systemic Lupus Erythematosus Treatment Market

  • 8.1. Asia-Pacific Systemic Lupus Erythematosus Treatment Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 8.3. Asia-Pacific Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

9. China Systemic Lupus Erythematosus Treatment Market

  • 9.1. China Systemic Lupus Erythematosus Treatment Market Overview
  • 9.2. China Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
  • 9.3. China Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

10. India Systemic Lupus Erythematosus Treatment Market

  • 10.1. India Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 10.2. India Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

11. Japan Systemic Lupus Erythematosus Treatment Market

  • 11.1. Japan Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 11.2. Japan Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

12. Australia Systemic Lupus Erythematosus Treatment Market

  • 12.1. Australia Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 12.2. Australia Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

13. Indonesia Systemic Lupus Erythematosus Treatment Market

  • 13.1. Indonesia Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 13.2. Indonesia Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

14. South Korea Systemic Lupus Erythematosus Treatment Market

  • 14.1. South Korea Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 14.2. South Korea Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

15. Western Europe Systemic Lupus Erythematosus Treatment Market

  • 15.1. Western Europe Systemic Lupus Erythematosus Treatment Market Overview
  • 15.2. Western Europe Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 15.3. Western Europe Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

16. UK Systemic Lupus Erythematosus Treatment Market

  • 16.1. UK Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 16.2. UK Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

17. Germany Systemic Lupus Erythematosus Treatment Market

  • 17.1. Germany Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 17.2. Germany Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

18. France Systemic Lupus Erythematosus Treatment Market

  • 18.1. France Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 18.2. France Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

19. Eastern Europe Systemic Lupus Erythematosus Treatment Market

  • 19.1. Eastern Europe Systemic Lupus Erythematosus Treatment Market Overview
  • 19.2. Eastern Europe Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 19.3. Eastern Europe Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

20. Russia Systemic Lupus Erythematosus Treatment Market

  • 20.1. Russia Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 20.2. Russia Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

21. North America Systemic Lupus Erythematosus Treatment Market

  • 21.1. North America Systemic Lupus Erythematosus Treatment Market Overview
  • 21.2. North America Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 21.3. North America Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

22. USA Systemic Lupus Erythematosus Treatment Market

  • 22.1. USA Systemic Lupus Erythematosus Treatment Market Overview
  • 22.2. USA Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 22.3. USA Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

23. South America Systemic Lupus Erythematosus Treatment Market

  • 23.1. South America Systemic Lupus Erythematosus Treatment Market Overview
  • 23.2. South America Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 23.3. South America Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

24. Brazil Systemic Lupus Erythematosus Treatment Market

  • 24.1. Brazil Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 24.2. Brazil Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

25. Middle East Systemic Lupus Erythematosus Treatment Market

  • 25.1. Middle East Systemic Lupus Erythematosus Treatment Market Overview
  • 25.2. Middle East Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 25.3. Middle East Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

26. Africa Systemic Lupus Erythematosus Treatment Market

  • 26.1. Africa Systemic Lupus Erythematosus Treatment Market Overview
  • 26.2. Africa Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 26.3. Africa Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

27. Systemic Lupus Erythematosus Treatment Market Competitive Landscape And Company Profiles

  • 27.1. Systemic Lupus Erythematosus Treatment Market Competitive Landscape
  • 27.2. Systemic Lupus Erythematosus Treatment Market Company Profiles
    • 27.2.1. GlaxoSmithKline PLC
      • 27.2.1.1. Overview
      • 27.2.1.2. Products and Services
      • 27.2.1.3. Strategy
      • 27.2.1.4. Financial Performance
    • 27.2.2. Aurinia Pharmaceuticals
      • 27.2.2.1. Overview
      • 27.2.2.2. Products and Services
      • 27.2.2.3. Strategy
      • 27.2.2.4. Financial Performance
    • 27.2.3. Pfizer
      • 27.2.3.1. Overview
      • 27.2.3.2. Products and Services
      • 27.2.3.3. Strategy
      • 27.2.3.4. Financial Performance
    • 27.2.4. Merck & Co
      • 27.2.4.1. Overview
      • 27.2.4.2. Products and Services
      • 27.2.4.3. Strategy
      • 27.2.4.4. Financial Performance
    • 27.2.5. Anthera Pharmaceuticals
      • 27.2.5.1. Overview
      • 27.2.5.2. Products and Services
      • 27.2.5.3. Strategy
      • 27.2.5.4. Financial Performance

28. Key Mergers And Acquisitions In The Systemic Lupus Erythematosus Treatment Market

29. Systemic Lupus Erythematosus Treatment Market Future Outlook and Potential Analysis

30. Appendix

  • 30.1. Abbreviations
  • 30.2. Currencies
  • 30.3. Historic And Forecast Inflation Rates
  • 30.4. Research Inquiries
  • 30.5. The Business Research Company
  • 30.6. Copyright And Disclaimer
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제